GENELUX Corp — Director's Dealing 2026

Jan 7, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GENELUX Corp (GNLX)
CIK: 0001231457
Period of Report: 2026-01-02

Reporting Person: Litten Jason (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-02	Stock Option (Right to Buy)	$4.55	A	275000	Acquired	2036-01-01	Common Stock (275000)	Direct

Footnotes

F1: The shares subject to the option will vest 25% on the first anniversary of the grant date, and the remaining shares will vest in 36 equal monthly installments thereafter.